Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 460-466

  Rubbia Brandt, Laura ^a,c   Audard, V ^b   Sartoretti, P ^a   Roth, A D ^a   Brezault, C ^b   Le Charpentier, M ^b   Dousset, B ^b   Morel, P ^a   Soubrane, O ^b   Chaussade, S ^b   Mentha, G ^a   Terris, B ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hôpital Cochin ^*  (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

5 fluorouracil; Drug liver injury; Neo adjuvant chemotherapy; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

ALPHA ACTIN; CD31 ANTIGEN; CELLULAR RETINOL BINDING PROTEIN; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; POLYCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; FATTY LIVER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER HEMORRHAGE; LIVER HYPERPLASIA; LIVER INJURY; LIVER METASTASIS; LIVER NECROSIS; LIVER RESECTION; LIVER SINUSOID; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MORPHOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SMOOTH MUSCLE; STELLATE CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 11144354740     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh095     Document Type: Article

References (31)

1. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-1410.
2. Minagawa M, Makuuchi M, Torzilli G et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann Surg 2000; 231: 487-499.
3. Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001; 12: 887-894.
4. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
5. Mathijssen RH, van Alphen RJ, Verweij J et al. Clinical pharmacokinetics and metabolism of irinotecan. Clin Cancer Res 2001; 7: 2182-2194.
6. Carrato A, Gallego J, Diaz-Rubio E. Oxaliplatin: Results in colorectal carcinoma. Crit Rev Oncol Hematol 2002; 44: 29-44.
7. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
8. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
9. Souglakos J, Mavroudis D, Kakolyris S et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002; 20: 2651-2657.
10. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
11. Schmoll HJ. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: Prospects and future directions. Semin Oncol 2002; 29: 34-39.
12. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25: 40-46.
13. Washington K, Lane KL, Meyers WC. Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 1993; 17: 1151-1158.
14. Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26: 524-535.
15. Cwikiel M, Zhang B, Eskilsson J et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995; 9: 561-576.
16. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
17. DeLeve LD, McCuskey RS, Wang X et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779-1791.
18. Eberhardt W, Beeg T, Beck KF et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 2000; 57: 59-69.
19. Uchio K, Tuchweber B, Manabe N et al. Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts. Lab Invest 2002; 82: 619-628.
20. Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology 1999; 34: 66-70.
21. Yeong ML, Wakefield SJ, Ford HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int J Exp Pathol 1993; 74: 211-217.
22. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11: 787-797.
23. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology 1997; 26: 343-350.
24. Misset JL, Bleiberg H, Sutherland W et al. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000; 35: 75-93.
25. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29: 11-20.
26. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
27. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483.
28. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23: 589-599.
29. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60: 143-154.
30. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000; 31: 428-434.
31. Liu J, Li C, Waalkes MP et al. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 2003; 37: 324-333.